IP Library Granted Patent US 8,486,454
Granted Patent B2
US 8,486,454 · App. 11/540,460 · Granted Jul 16, 2013

Method of attenuating neurogenic pain

Inventors: Robert W. Sessions (Burr Ridge, IL); Alan R. Kahn (Minneapolis, MN)
Assignee: Sessions Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,486,454
App. No.
11/540,460
Granted
Jul 16, 2013
Kind
B2
Abstract

The present invention provides a method of attenuating the formation or reducing the severity of neurogenic pain in the tissue of a patient via applying a composition comprising a hydrophilic foam substrate and a polymeric hydrophilic agent to a portion of the surface of the skin in an amount and at a location sufficient to attenuate formation of or reduce the severity of neurogenic pain.

Claims (19)

1. A method of treating neurogenic pain within the muscle, bone, ligamentous, or joint tissue of a patient, the method comprising applying a composition comprising a hydrophilic foam substrate and a hydrophilic agent to a portion of the patient's skin in an amount sufficient to treat the neurogenic pain, wherein said portion of said skin is unbroken.

2. The method of claim 1 , wherein the hydrophilic foam comprises the in situ reaction product of an isocyanate-capped polyether prepolymer.

3. The method of claim 2 , wherein the prepolymer is selected from the group consisting of isocyanate-capped polyether polyols having an isocyanate equivalent weight of from about 0.5 meq/g to about 3.0 meq/g and mixtures thereof.

4. The method of claim 1 , wherein the hydrophilic agent is capable of absorbing water.

5. The method of claim 1 , wherein the hydrophilic agent is polymeric.

6. The method of claim 1 , wherein the hydrophilic agent is selected from the group consisting of starch grafted copolymers of acrylate salts, starch grafted copolymers of acrylamide salts, polyacrylate salts, and mixtures thereof.

7. The method of claim 1 , wherein the hydrophilic agent comprises an additive selected from the group consisting of methylcellulose, guar gum, pectin, karaya gum, chitosan, agar, acacia powder, carrageenan, gelatin, and mixtures thereof.

8. The method of claim 1 , wherein the hydrophilic agent is incorporated into the foam substrate.

9. The method of claim 1 , wherein the composition further comprises an alcohol.

10. The method of claim 9 , wherein the alcohol is selected from the group consisting of water soluble monols, diols and polyhydric alcohols.

11. The method of claim 9 , wherein the alcohol is selected from the group consisting of ethanol, isopropyl alcohol, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin, 1,2,4-butanetriol, trimethylolpropane, sorbitol, pentaerythritol, and mixtures thereof.

12. The method of claim 9 , wherein the alcohol is incorporated into the foam substrate.

13. The method of claim 1 , wherein the composition further comprises a therapeutic agent.

14. The method of claim 13 , wherein the therapeutic agent is selected from the group consisting of soluble collagen, hydrolyzed collagen, collagen amino acids salt free, hydrolyzed animal protein and hyaluronic acid, an ointment including methyl salicylate and menthol and hydrocortisone acetate, polymers with medicinal properties, and trans-retinoic acid.

15. The method of claim 13 , wherein the therapeutic agent is incorporated into the foam substrate.

16. The method of claim 1 , which further comprises a wetting agent.

17. The method of claim 16 , wherein the wetting agent is a non-ionic surfactant selected from the group consisting of block copolymers of ethylene oxide and propylene oxide, ethoxylated sorbitan fatty acid esters, glycerol esters, polyglycerol esters, silicone fluids and mixtures thereof.

18. The method of claim 16 , wherein the wetting agent is incorporated into the foam substrate.

19. The method of claim 1 , wherein the patient is a human.

Assignments (3)
CHANGE OF NAME Recorded Dec 23, 2009
From: FERRIS PHARMACEUTICALS INC.
To: SESSIONS PHARMACEUTICALS INC.
Reel/Frame 023699/0129 →
CHANGE OF NAME Recorded Sep 16, 2009
From: FERRIS CORP.
To: FERRIS PHARMACEUTICALS INC.
Reel/Frame 023241/0348 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2009
From: SESSIONS, ROBERT W; KAHN, ALAN R
To: FERRIS CORPORATION
Reel/Frame 023226/0182 →
Continuity (6)
Continuation 11440550 · May 25, 2006
Continuation 10175119 · Jun 19, 2002
Continuation 09789275 · Feb 20, 2001
Division 09326836 · Jun 7, 1999
Provisional Application 60088424 · Jun 8, 1998
Related Publication 20070025922A1 · Feb 1, 2007